StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/30111% above fair value
$332.29+7.74 (+2.38%)

Close on Oct 30, 2026Market cap $9.84BP/E 41.6Yield –

Earnings

Krystal Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 2, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$119.20M
+24.2% on a year earlier
EPS, Q2 FY2026
$1.79
$1.29 a year earlier
Latest guidance
Reaffirmed
Aug 3, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Krystal Biotech's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 2, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 3, 2026before the open$119.20M+24.2%$1.79Release
Q4 FY2025ended Dec 31, 2025Jan 12, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025before the open$97.80M+16.7%$2.66Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025before the open$96.00M+36.6%$1.29Release
Q1 FY2025ended Mar 31, 2025May 6, 2025before the open$88.20M+94.7%$1.20Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024before the open$83.80M+874.4%$0.91Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024before the open$70.30M–$0.53Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$45.30M–$0.03Release
Q4 FY2023ended Dec 31, 2023Feb 26, 2024before the open$42.10M–$0.30Release
Q3 FY2023ended Sep 30, 2023Nov 6, 2023before the open$8.60M–$2.79Release
Q2 FY2023ended Jun 30, 2023Aug 7, 2023before the open––-$1.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Krystal Biotech's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
combined non-GAAP R&D and SG&A expensenon-GAAPFY2026$175.00M – $195.00M–NewJan 12, 2026
Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expensenon-GAAPFY2026$175.00M – $195.00M–ReaffirmedAug 3, 2026

Guidance history

Every forecast Krystal Biotech put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 3, 2026Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2026$175.00M – $195.00MReaffirmed
Jan 12, 2026combined non-GAAP R&D and SG&A expenseFY2026$175.00M – $195.00MNew
Nov 3, 2025Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2025$145.00M – $155.00MLowered
Aug 4, 2025Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2025$150.00M – $175.00MNew
May 6, 2025Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2025$150.00M – $175.00MNew
Nov 4, 2024combined R&D and SG&A expenseFY2024$115.00M – $125.00MLowered
Aug 5, 2024Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2024$150.00M – $175.00MReaffirmed
May 6, 2024Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2024$150.00M – $175.00MReaffirmed
Feb 26, 2024Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expenseFY2024$150.00M – $175.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Krystal Biotech filed with the SEC as exhibits to Form 8-K or 6-K

  1. Krystal Biotech Announces Positive Clinical Data for New
    Update
  2. 8-K exhibit EX-99.2
    Update
  3. Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
    Results
  4. 8-K exhibit EX-99.1
    News
  5. Krystal Biotech Announces Fourth Quarter and Full Year 2025
    Results
  6. Krystal Biotech Provides Business Update at 44 th Annual J.P. Morgan Healthcare Conference
    Results
  7. Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
    Update
  8. 8-K exhibit EX-99.2
    Update
  9. Krystal Biotech Announces Third Quarter 2025
    Results
  10. Krystal Biotech Announces Second Quarter 2025
    Results
  11. Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
    Update
  12. Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
    Update
  13. July 2025 1 KB304 PEARL-2 Results for Dynamic Wrinkles of the Décolleté r e p l e n i s h r e s t o r e Exhibit 99.2
    Update
  14. Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
    Update
  15. 8-K exhibit EX-99.2
    Update